Grazax in children

Grazax, the grass-pollen allergen tablet from ALK-Abello, has had its licence extended to include use in children and adolescents aged five to 17 years.

The fast-melting sublingual tablet for once-daily administration is indicated for the treatment of grass pollen-induced rhinitis and conjunctivitis.

Grazax is non-injection immunotherapy and the first dose should be given under medical supervision.

View Grazax drug record

Further information: ALK-Abello

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Further monthly injectable migraine prophylactic launched

Further monthly injectable migraine prophylactic launched

With the launch of Emgality (galcanezumab), prescribers...

Vitamin D3 Supplements

Formulations and indications of colecalciferol preparations.

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Treatment with febuxostat (Adenuric) should be avoided...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Colestid Orange. Use our constantly updated...